Safe Biologics

NOVEMBER 12, 2023

6 “The Biosimilar Red Tape Elimination Act”, which would prevent the HHS Secretary from requiring switching studies in order for a biosimilar to be deemed “interchangeable” Under U.S. state law, only biosimilars which are interchangeable may be substituted by a pharmacist without contacting the prescriber.

Biosimilars 130

Biosimilars Drug Pricing Packaging Labelling 130

Safe Biologics

DECEMBER 3, 2023

ASBM and GaBI Webinar Examines Policy Challenges to Interchangeable Biosimilars On November 30, ASBM and the Generics and Biosimilars Initiative (GaBI) hosted I nterchangeable Designation for Biosimilars- Ensuring Continuity of Patient Care: Upholding Interchangeability Status for Biosimilars.

Biosimilars 130

Biosimilars Labelling Drug Pricing Packaging 130

Safe Biologics

DECEMBER 6, 2023

prescribers have high confidence in the safety and efficacy of biosimilars, a majority (58%) oppose third-party switching of a patient’s biologic medicine for non-medical (e.g. state law, only biosimilars which are interchangeable may be substituted by a pharmacist without contacting the prescriber. and worldwide.”

Biosimilars 130

Biosimilars Packaging Labelling Drug Development 130

Drug Patent Watch

JANUARY 7, 2025

The Importance of Generic Drugs in Healthcare Generic drugs offer several benefits to patients and the healthcare system: Cost-effectiveness: Generic drugs are typically much cheaper than brand-name medications, making treatment more accessible to patients. Food and Drug Administration. ” FDA.gov, 2021.

Communication 89

Communication Dosage Drug Pricing Packaging 89

HealthPartners

JULY 21, 2021

This integrated approach keeps everything together in one package that is coordinated by your primary medical health plan vendor. For example, members can compare drug prices at pharmacies or find a network provider. This results is savings of 80% off the list price of generic biologics rather than discounts of 55-60%.

Biosimilars 52

Biosimilars Specialty Pharmacies Mail-Order Pharmacies Health Insurance Companies 52

pharmaphorum

JANUARY 22, 2021

We don’t believe there will be draconian price cuts, for the same reason. The Biden administration could put additional scrutiny on drug prices, but more drastic measures, such as allowing Medicare to negotiate with pharma companies directly, are still unlikely.”.

Drug Pricing 63

Drug Pricing Packaging Biosimilars Pharmaceutical Companies 63